Publication details
Dapagliflozin a studie DECLARE – vstupní charakteristika
| Title in English | Dapagliflozin and the DECLARE study - Input characteristic |
|---|---|
| Authors | |
| Year of publication | 2018 |
| Type | Article in Periodical |
| Magazine / Source | Kardiologická revue - Interní medicína |
| MU Faculty or unit | |
| Citation | |
| Keywords | Dapagliflozin; Declare; baseline characteristics |
| Description | Gliflozins - SGLT2 - mean a new approach to the treatment of type 2 diabetes mellitus. The mechanism of action is the excretion of excess sugar via the kidneys. In 2015, the first mortality study with SGLT2 empagliflozin - EMPA-REG OUTCOME was completed, in 2017 the CANVAS programme with canagliflozin were published and further studies are ongoing. An extensive programme has been launched with dapagliflozin, where meta-analyses of smaller studies have shown very positive results in reducing cardiovascular events. A large international clinical trial with dapagliflozin has been going on under the name DECLARE, scheduled to be completed in the summer of 2018. At the beginning of 2018, the initial characteristics of the patients enrolled in this study were published. The study included 17,160 patients with type 2 diabetes mellitus who were randomized to placebo or dapagliflozin at 10 mg/day. The mean age of the patients was 63.8 +- 6.8 years, mean duration of diabetes 11.8 +- 7.8 years, mean glycated haemoglobin 8.3% +- 1.2%. A total of 6,971 (40.6%) patients had confirmed cardiovascular disease and 10,189 (59.4%) had multiple risk factors. |